Bolt Biotherapeutics(BOLT) - 2022 Q4 - Annual Report

Item 1. Business. Our Boltbody ISACs are delivered systemically but act locally through a highly targeted approach that triggers a localized anti-tumor immune cascade through a "Three-Factor Authentication" process. This process is designed to optimize safety and minimize adverse, non-tumor-targeted systemic immune stimulation as follows: 1. Tumor antigen recognition: Our selective and specific Boltbody ISACs bind specifically to the target antigen, recognizing tumors that express the target antigen. 2. Ant ...